Clinical and economic outcomes of robotic-assisted, laparoscopic, and open liver resection in BCLC 0/A hepatocellular carcinoma: a nationwide cohort study.
[BACKGROUND AND AIM] Hepatectomy remains the standard treatment for Barcelona Clinic Liver Cancer (BCLC) stage 0/A hepatocellular carcinoma (HCC).
- p-value P < 0.001
APA
Xia F, Liu X, et al. (2026). Clinical and economic outcomes of robotic-assisted, laparoscopic, and open liver resection in BCLC 0/A hepatocellular carcinoma: a nationwide cohort study.. International journal of surgery (London, England), 112(2), 4166-4178. https://doi.org/10.1097/JS9.0000000000003938
MLA
Xia F, et al.. "Clinical and economic outcomes of robotic-assisted, laparoscopic, and open liver resection in BCLC 0/A hepatocellular carcinoma: a nationwide cohort study.." International journal of surgery (London, England), vol. 112, no. 2, 2026, pp. 4166-4178.
PMID
41287872
Abstract
[BACKGROUND AND AIM] Hepatectomy remains the standard treatment for Barcelona Clinic Liver Cancer (BCLC) stage 0/A hepatocellular carcinoma (HCC). However, debates persist regarding the optimal surgical approach - robot-assisted (RALR), laparoscopic (LLR), or open liver resection (OLR) - due to differences in perioperative outcomes, recurrence, and cost-effectiveness. While minimally invasive techniques offer potential advantages, such as reduced morbidity and faster recovery, their comprehensive impact remains unclear. This study evaluates and compares the intraoperative, postoperative, and economic outcomes of these three approaches in a multicenter cohort of BCLC 0/A HCC patients.
[METHOD] Propensity score matching (PSM) was used to balance baseline characteristics across RALR, LLR, and OLR groups (714 patients each). Intraoperative and postoperative outcomes, as well as recurrence-free survival and overall survival, were assessed. Cost-effectiveness was assessed based on quality-adjusted life years (QALYs) and incremental cost-effectiveness ratios (ICERs).
[RESULT] This nationwide retrospective study analyzed 2882 BCLC 0/A HCC patients from 27 centers. After PSM, 2142 patients were analyzed (714 in each group). Operative time was longer in RALR (225 min) and LLR (225 min) compared to OLR (170 min, P < 0.001). Postoperative complication rates were lower in RALR (12.5%) and LLR (13.4%) than in OLR (17.1%), with fewer severe complications. The OLR group had a higher proportion of advanced-stage recurrences (BCLC B/C/D: 70.3%) versus RALR (37.9%) and LLR (35.9%) ( P < 0.001). RALR achieved the highest 5-year QALYs (1.143) among the three groups, while LLR demonstrated superior cost-effectiveness with an ICER of -$24 379/QALY compared to OLR.
[CONCLUSION] RALR and LLR demonstrated lower incidence and severity of complications, less advanced-stage recurrence, and higher cost-effectiveness compared to OLR. These findings support the broader adoption of minimally invasive techniques to improve long-term outcomes and quality of life (QoL). Despite RALR's higher initial costs, it remains a highly cost-effective option, offering superior QoL and long-term economic benefits.
[METHOD] Propensity score matching (PSM) was used to balance baseline characteristics across RALR, LLR, and OLR groups (714 patients each). Intraoperative and postoperative outcomes, as well as recurrence-free survival and overall survival, were assessed. Cost-effectiveness was assessed based on quality-adjusted life years (QALYs) and incremental cost-effectiveness ratios (ICERs).
[RESULT] This nationwide retrospective study analyzed 2882 BCLC 0/A HCC patients from 27 centers. After PSM, 2142 patients were analyzed (714 in each group). Operative time was longer in RALR (225 min) and LLR (225 min) compared to OLR (170 min, P < 0.001). Postoperative complication rates were lower in RALR (12.5%) and LLR (13.4%) than in OLR (17.1%), with fewer severe complications. The OLR group had a higher proportion of advanced-stage recurrences (BCLC B/C/D: 70.3%) versus RALR (37.9%) and LLR (35.9%) ( P < 0.001). RALR achieved the highest 5-year QALYs (1.143) among the three groups, while LLR demonstrated superior cost-effectiveness with an ICER of -$24 379/QALY compared to OLR.
[CONCLUSION] RALR and LLR demonstrated lower incidence and severity of complications, less advanced-stage recurrence, and higher cost-effectiveness compared to OLR. These findings support the broader adoption of minimally invasive techniques to improve long-term outcomes and quality of life (QoL). Despite RALR's higher initial costs, it remains a highly cost-effective option, offering superior QoL and long-term economic benefits.
MeSH Terms
Humans; Carcinoma, Hepatocellular; Liver Neoplasms; Hepatectomy; Robotic Surgical Procedures; Male; Female; Laparoscopy; Middle Aged; Retrospective Studies; Aged; Cost-Benefit Analysis; Treatment Outcome; Propensity Score; Quality-Adjusted Life Years; Operative Time
같은 제1저자의 인용 많은 논문 (4)
- FIG4 downregulation-arrested autophagy-lysosomal degradation of IL-18 drives lipid-associated macrophage polarization and immunotherapy resistance in triple-negative breast cancer.
- A novel pathologic scoring system for predicting postoperative recurrence in BCLC stage 0-A hepatocellular carcinoma patients: a nationwide multicenter study.
- Risk factors for hepatocellular carcinoma rupture: multicentre retrospective study.
- Refining Prognosis and Treatment Strategies Beyond the Barcelona Clinic Liver Cancer Stage in Hepatocellular Carcinoma with Lung Metastases: A Multicenter Cohort Study.